Casi pharmaceuticals acquires global intellectual property rights to cleave therapeutics' vcp/p97 inhibitor cb-5339

Beijing , july 20, 2023 /prnewswire/ -- casi pharmaceuticals, inc. (nasdaq: casi), a biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today announced the execution of the assignment agreement (the "agreement") with cleave therapeutics, inc. ("cleave"), pursuant to which casi obtained all rights and global intellectual property rights related to cb-5339, a novel vcp/p97 inhibitor, as well as all remaining cb-5339 drug substance and drug product. additionally, casi will assume responsibility of the united states ("us") cb-5339 investigational new drug ("ind") application.
CASI Ratings Summary
CASI Quant Ranking